SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-206227
Filing Date
2023-08-08
Accepted
2023-08-08 16:15:35
Documents
14
Period of Report
2023-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d552362d8k.htm   iXBRL 8-K 24708
2 EX-99.1 d552362dex991.htm EX-99.1 48063
6 GRAPHIC g552362g0805003908396.jpg GRAPHIC 3298
  Complete submission text file 0001193125-23-206227.txt   207859

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20230808.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20230808_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20230808_pre.xml EX-101.PRE 11265
8 EXTRACTED XBRL INSTANCE DOCUMENT d552362d8k_htm.xml XML 3359
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 231151528
SIC: 2834 Pharmaceutical Preparations